Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells

Abstract

PurposeTargeting cancer cells by modulating the immune system has become an important new therapeutic option in many different malignancies. Inhibition of CTLA4/B7 and PD1/PDL1 signaling is now also being investigated and already successfully applied to various hematologic malignancies.MethodsA literature review of PubMed and results of our own studies were compiled in order to give a comprehensive overview on this topic.ResultsWe elucidate the pathophysiological role of immunosuppressive networks in lymphomas, ranging from changes in the cellular microenvironment composition to distinct signaling pathways such as PD1/PDL1 or CTLA4/B7/CD28. The prototypical example of a lymphoma manipulating and thereby silencing the immune system is Hodgkin lymphoma. Also other lymphomas, e.g., primary mediastinal B-cell lymphoma and some Epstein–Barr virus (EBV)-driven malignancies, use analogous survival strategies, while diffuse large B-cell lymphoma of the activated B-cell type, follicular lymphoma and angioimmunoblastic T-cell lymphoma to name a few, exert further immune escape strategies each. These insights have already led to new treatment opportunities and results of the most important clinical trials based on this concept are briefly summarized. Immune checkpoint inhibition might also have severe side effects; the mechanisms of the rather un(der)recognized hematological side effects of this treatment approach are discussed.ConclusionSilencing the host’s immune system is an important feature of various lymphomas. Achieving a better understanding of distinct pathways of interactions between lymphomas and different immunological microenvironment compounds yields substantial potential for new treatment concepts.

CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model

“…The tumor microenvironment plays a critical role in lymphoma pathogenesis, with immunomodulatory and immune evasion strategies facilitating tumor growth (1). Immunotherapy is a rapidly growing area of translational research in this field, and immune checkpoint inhibitors that activate effector T-cell function by blocking the PD-1/PD-L1 and CTLA-4/B7 pathways to reactivate the activity of effector T cells have already shown promise in hematological malignancies (2).…”

Research Article Association of HLA-G 14-base pair insertion/deletion polymorphism with breast cancer in Saudi Arabia

“…Approximately 50 polymorphic sites have been mapped either in non-coding or coding regions (IMGT HLA database, December 2013). The HLA-G molecule was reported for its tolerogenic function mainly in the maternal-fetal interface, helping to protect the fetus from destruction by the mother's immune defense system (Kovats et al, 1990;Menter and Tzankov, 2018;Galaviz-Hernandez et al, 2019). Considering the tolerogenic properties of the HLA-G molecule, many studies have detected an association between the aberrant expression of HLA-G and the occurrence of several types of malignancies such as colorectal cancer, esophageal cancer, uterine cervical cancer, ovarian carcinoma, hepatocellular carcinoma, carcinoma of bladder, and breast cancer (Rouas-Freiss et al, 2005a;Zidi and Ben Amor, 2011;Kim et al, 2013;Rolfsen et al, 2014;Rutten et al, 2014;Zhang and Tao Wang, 2014;Zidi et al, 2016;Zambra et al, 2016;de Almeida et al, 2018;Lin and Yan, 2018) as well as several other diseases such as infections, autoimmunity, and abortion (Donadi et al, 2011;Vargas et al, 2011;Garcia et al, 2013;Dias et al, 2015;Sabbagh et al, 2018;).…”

Cardiac Extracellular Vesicles (EVs) Released in the Presence or Absence of Inflammatory Cues Support Angiogenesis in Different Manners

“…In contrast, a rogue communication can affect the homeostasis of an organism and manifest diseases. Malignant degenerated cells, for example, have altered their communication to facilitate the formation of metastases and to evade immune responses [8,9].…”